Liraglutide Pen Injector + Placebo Pen Injector
Phase 2Terminated 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pouchitis
Conditions
Pouchitis, Irritable Pouch Syndrome
Trial Timeline
Mar 22, 2022 → Oct 16, 2023
NCT ID
NCT04763564About Liraglutide Pen Injector + Placebo Pen Injector
Liraglutide Pen Injector + Placebo Pen Injector is a phase 2 stage product being developed by Novo Nordisk for Pouchitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT04763564. Target conditions include Pouchitis, Irritable Pouch Syndrome.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04763564 | Phase 2 | Terminated |
Competing Products
3 competing products in Pouchitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Mirikizumab - Intravenous (IV) + Mirikizumab - Subcutaneous (SC) | Eli Lilly | Approved | 85 |
| etrasimod + Placebo | Pfizer | Phase 2 | 51 |
| Rifaximin 550 MG Oral Tablet [XIFAXAN] | Bausch Health | Approved | 80 |